EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein

John M Powers, Zoe L Lyski, Whitney C Weber, Michael Denton, Magdalene M Streblow, Adam T Mayo, Nicole N Haese, Chad D Nix, Rachel Rodríguez-Santiago, Luisa I Alvarado, Vanessa Rivera-Amill, William B Messer und 1 weitere

PLOS Neglected Tropical Diseases · 13.03.2023 · 17 (3) · e0011154

DOI: 10.1371/journal.pntd.0011154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 13.03.2023. Verfasst von John M Powers und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America. Hauptthemen laut MEDLINE: Chikungunya virus, Chikungunya Fever. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, ACL HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infections with Chikungunya virus, a mosquito-borne alphavirus, cause an acute febrile syndrome often followed by chronic arthritis that persists for months to years post-infection. Neutralizing antibodies are the primary immune correlate of protection elicited by infection, and the major goal of vaccinations in development. Using convalescent blood samples collected from both endemic and non-endemic human subjects at multiple timepoints following suspected or confirmed chikungunya infection, we identified antibodies with broad neutralizing properties against other alphaviruses within the Semliki Forest complex. Cross-neutralization generally did not extend to the Venezuelan Equine Encephalitis virus (VEEV) complex, although some subjects had low levels of VEEV-neutralizing antibodies. This suggests that broadly neutralizing antibodies elicited following natural infection are largely complex restricted. In addition to serology, we also performed memory B-cell analysis, finding chikungunya-specific memory B-cells in all subjects in this study as remotely as 24 years post-infection. We functionally assessed the ability of memory B-cell derived antibodies to bind to chikungunya virus, and related Mayaro virus, as well as the highly conserved B domain of the E2 glycoprotein thought to contribute to cross-reactivity between related Old-World alphaviruses. To specifically assess the role of the E2 B domain in cross-neutralization, we depleted Mayaro and Chikungunya virus E2 B domain specific antibodies from convalescent sera, finding E2B depletion significantly decreases Mayaro virus specific cross-neutralizing antibody titers with no significant effect on chikungunya virus neutralization, indicating that the E2 B domain is a key target of cross-neutralizing and potentially cross-protective neutralizing antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chikungunya virusChikungunya FeverAnimalsHumansBroadly Neutralizing AntibodiesAntibodies, ViralAntibodies, NeutralizingGlycoproteins

Substanzen

Broadly Neutralizing AntibodiesAntibodies, ViralAntibodies, NeutralizingGlycoproteins

Autor:innen und Institutionen

  • Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
  • Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Ponce Health Sciences University/ Ponce Research Institute, Ponce, Puerto Rico.
  • Department of Medicine, Division of Infectious Disease Oregon Health and Science University, Portland, Oregon, United States of America.
  • OHSU-PSU School of Public Health, Program in Epidemiology, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, Oregon, United States of America.

ORCID-Profile: Daniel N Streblow

Förderung

  • NIAID NIH HHS
  • ACL HHS
  • NCATS NIH HHS
  • NIGMS NIH HHS
  • NCEZID CDC HHS
  • Foundation for the National Institutes of Health
  • Takeda Science Foundation
  • Sunlin and Priscilla Chou Foundation

Zitieren

APA

Powers, J. M., Lyski, Z. L., Weber, W. C., Denton, M., Streblow, M. M., Mayo, A. T., Haese, N. N., Nix, C. D., Rodríguez-Santiago, R., Alvarado, L. I., Rivera-Amill, V., Messer, W. B., & Streblow, D. N. (2023). Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein. PLOS Neglected Tropical Diseases, 17(3), e0011154. https://doi.org/10.1371/journal.pntd.0011154

Vancouver

Powers JM, Lyski ZL, Weber WC, Denton M, Streblow MM, Mayo AT, et al. Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein. PLOS Neglected Tropical Diseases. 2023;17(3):e0011154. doi:10.1371/journal.pntd.0011154

BibTeX
@article{Powers2023,
  author = {Powers, John M and Lyski, Zoe L and Weber, Whitney C and Denton, Michael and Streblow, Magdalene M and Mayo, Adam T and Haese, Nicole N and Nix, Chad D and Rodríguez-Santiago, Rachel and Alvarado, Luisa I and Rivera-Amill, Vanessa and Messer, William B and Streblow, Daniel N},
  title = {Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  volume = {17},
  number = {3},
  pages = {e0011154},
  doi = {10.1371/journal.pntd.0011154}
}
Kostenlos starten →